# Exagen Inc.

> clinical laboratory company

**Wikidata**: [Q106435940](https://www.wikidata.org/wiki/Q106435940)  
**Source**: https://4ort.xyz/entity/exagen-inc

## Summary
Exagen Inc. is a clinical laboratory company specializing in diagnostic testing, particularly for autoimmune diseases like lupus erythematosus. Founded in 2002 and headquartered in Vista, California, it operates as a public company listed on the Nasdaq under the ticker symbol XGN since September 19, 2019.

## Key Facts
- Founded in 2002 and headquartered in Vista, California (ZIP code 92081).
- Publicly traded on the Nasdaq under the ticker symbol **XGN** since September 19, 2019.
- Specializes in medical testing, with a focus on autoimmune diseases, including lupus erythematosus.
- Operates under the legal form of a **public company**, offering securities to the general public.
- Generated **$42 million in revenue** in 2020.
- Official name: **Exagen Inc.**, with aliases including **Exagen**, **AVISE Test**, **AVISE**, and **Exagen Diagnostics**.
- Key executives include **John Aballi** (CEO) and **Kamal Adawi** (CFO).
- Industry classification: **Medical Laboratories** (NAICS code 621511) within the **life sciences** sector.
- Social media presence includes Twitter (**@ExagenInc**), Facebook (**ExagenInc**), and LinkedIn (**exageninc**).
- Website: [https://exagen.com](https://exagen.com) (active since May 6, 2016).
- Corporate identifiers:
  - **ISIN**: US30068X1037
  - **ISNI**: 000000040507341X
  - **Central Index Key (CIK)**: 0001274737
  - **Ringgold ID**: 10901
  - **Crunchbase Organization ID**: exagen-diagnostics

## FAQs
**What does Exagen Inc. do?**
Exagen Inc. is a clinical laboratory company that develops and provides diagnostic tests, primarily for autoimmune diseases such as lupus erythematosus. Its tests, including the **AVISE Test**, help clinicians diagnose and monitor these conditions more accurately.

**When was Exagen Inc. founded, and where is it based?**
The company was founded in **2002** and is headquartered in **Vista, California (92081)**.

**Is Exagen Inc. a public company?**
Yes, Exagen Inc. has been a **publicly traded company** since its initial public offering (IPO) on **September 19, 2019**, listed on the **Nasdaq** under the ticker symbol **XGN**.

**What are Exagen Inc.’s key products or services?**
Exagen specializes in **diagnostic testing for autoimmune diseases**, with a focus on lupus erythematosus. Its **AVISE Test** is one of its notable offerings in this field.

**Who are the key executives at Exagen Inc.?**
As of the available data, **John Aballi** serves as the **Chief Executive Officer (CEO)**, and **Kamal Adawi** is the **Chief Financial Officer (CFO)**.

**How much revenue did Exagen Inc. generate in 2020?**
In **2020**, Exagen Inc. reported **$42 million in revenue**.

**What is Exagen Inc.’s stock symbol and exchange?**
Exagen Inc. trades on the **Nasdaq** under the ticker symbol **XGN**.

**What social media platforms is Exagen Inc. active on?**
Exagen Inc. maintains official accounts on **Twitter (@ExagenInc)**, **Facebook (ExagenInc)**, and **LinkedIn (exageninc)**.

## Why It Matters
Exagen Inc. plays a critical role in **advancing diagnostic precision for autoimmune diseases**, particularly lupus, which is notoriously difficult to diagnose. By providing specialized laboratory tests like the **AVISE Test**, the company helps clinicians improve **early detection, accurate diagnosis, and personalized treatment plans**, ultimately enhancing patient outcomes. As a **publicly traded company**, Exagen also contributes to the **life sciences and biotech investment ecosystem**, offering opportunities for investors to support innovation in medical diagnostics. Its focus on **autoimmune disease testing** addresses a significant unmet need in healthcare, where misdiagnosis and delayed treatment are common challenges.

## Notable For
- Developing the **AVISE Test**, a diagnostic tool for autoimmune diseases, particularly lupus erythematosus.
- Being a **publicly traded clinical laboratory company** (Nasdaq: XGN) since **2019**.
- Generating **$42 million in revenue in 2020**, demonstrating its commercial viability in the medical diagnostics sector.
- Operating in the **highly specialized field of autoimmune disease diagnostics**, a niche with significant clinical impact.
- Maintaining a strong **digital presence** across multiple platforms, including Twitter, Facebook, and LinkedIn, to engage with healthcare professionals and investors.
- Having a **dedicated leadership team**, including CEO John Aballi and CFO Kamal Adawi, guiding its strategic growth.

## Body

### **Company Overview and Legal Structure**
Exagen Inc. is a **clinical laboratory company** founded in **2002** and headquartered in **Vista, California (92081)**. It operates as a **public company**, meaning its securities are available for purchase by the general public. The company is listed on the **Nasdaq** under the ticker symbol **XGN**, having gone public on **September 19, 2019**. Its legal classification aligns with that of a **joint-stock company**, a structure that allows it to raise capital through public investment.

### **Industry and Field of Work**
Exagen Inc. operates within the **life sciences** sector, specifically under the **Medical Laboratories** industry (NAICS code **621511**). The company’s primary focus is on **diagnostic testing for autoimmune diseases**, with a particular emphasis on **lupus erythematosus**. Its proprietary tests, such as the **AVISE Test**, are designed to assist clinicians in diagnosing and monitoring these complex conditions more effectively.

### **Financial and Corporate Data**
- **Revenue**: In **2020**, Exagen Inc. reported **$42 million in revenue**, reflecting its growing presence in the medical diagnostics market.
- **Stock Exchange Listing**: The company trades on the **Nasdaq** under the symbol **XGN** since its IPO in **September 2019**.
- **Corporate Identifiers**:
  - **ISIN**: US30068X1037
  - **ISNI**: 000000040507341X
  - **Central Index Key (CIK)**: 0001274737
  - **Ringgold ID**: 10901
  - **Crunchbase Organization ID**: exagen-diagnostics

### **Leadership and Governance**
Exagen Inc. is led by a team of experienced executives:
- **John Aballi** serves as the **Chief Executive Officer (CEO)**.
- **Kamal Adawi** holds the position of **Chief Financial Officer (CFO)**.

The company’s governance structure follows standard corporate practices, with a **board of directors** overseeing strategic decisions and ensuring compliance with regulatory requirements.

### **Digital and Social Media Presence**
Exagen Inc. maintains an active **online presence** to engage with stakeholders, including healthcare professionals, investors, and patients:
- **Website**: [https://exagen.com](https://exagen.com) (launched **May 6, 2016**)
- **Twitter**: [@ExagenInc](https://twitter.com/ExagenInc) (active since **January 25, 2018**)
- **Facebook**: [ExagenInc](https://www.facebook.com/ExagenInc) (active since **January 21, 2019**)
- **LinkedIn**: [exageninc](https://www.linkedin.com/company/exageninc) (LinkedIn ID: **81063**)

### **Branding and Aliases**
Exagen Inc. is also known by several **aliases and brand names**, including:
- **Exagen**
- **AVISE Test**
- **AVISE**
- **Exagen Diagnostics**

These names are often used interchangeably in marketing, clinical, and investor communications.

### **Geographic and Operational Details**
- **Headquarters**: Vista, California (ZIP code **92081**)
- **Primary Market**: United States, with a focus on **autoimmune disease diagnostics**
- **Field of Work**: Specializes in **medical testing**, particularly for **lupus erythematosus** and other autoimmune conditions

### **Regulatory and Compliance**
As a **publicly traded company**, Exagen Inc. adheres to **strict financial reporting and disclosure standards** set by regulatory bodies such as the **U.S. Securities and Exchange Commission (SEC)**. Its **Central Index Key (CIK: 0001274737)** is used for SEC filings, ensuring transparency for investors.

### **Historical Context and Growth**
Since its founding in **2002**, Exagen Inc. has evolved from a private entity into a **publicly traded company**, completing its IPO in **2019**. This transition has allowed it to **expand its diagnostic capabilities**, invest in research and development, and increase its market reach. The company’s revenue growth, including **$42 million in 2020**, underscores its increasing role in the **medical diagnostics industry**.

### **Related Entities and Partnerships**
While the provided data does not specify partnerships, Exagen Inc.’s **public company status** and **Nasdaq listing** suggest it engages with **investors, healthcare providers, and research institutions** to advance its diagnostic solutions. Its **social media and digital presence** further indicate active engagement with both **clinical and financial communities**.

### **Future Outlook**
As a **publicly traded clinical laboratory company**, Exagen Inc. is positioned to **expand its diagnostic offerings**, particularly in **autoimmune disease testing**. Its focus on **lupus erythematosus** and related conditions addresses a critical gap in **precision medicine**, where accurate and timely diagnosis remains a challenge. Continued innovation and strategic growth could further solidify its role in the **life sciences and medical diagnostics sectors**.

## References

1. [Crunchbase](http://www.crunchbase.com/organization/exagen-diagnostics)
2. International Standard Name Identifier
3. [Source](https://sec.report/Document/0001274737-21-000015/#i46297aecc50342189ce6ad0511b1efd6_94)